Prime Capital Investment Advisors
IBRX icon

Prime Capital Investment Advisors’s ImmunityBio IBRX Stock Holding History

Prime Capital Investment Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174K Buy
19,870
+1,000
+5% +$7.57K ﹤0.01% 1037
2026
Q1 		$145K Buy
+18,870
New +$129K ﹤0.01% 996

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Prime Capital Investment Advisors's IBRX Position: Q2 2026 in Review

Prime Capital Investment Advisors increased its ImmunityBio (IBRX) stake by 5.3% in Q2 2026, buying an estimated $7.57K and bringing the position to 19,870 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

Prime Capital Investment Advisors first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Prime Capital Investment Advisors held 19,870 shares of ImmunityBio worth $174K as of Q2 2026.
  • Prime Capital Investment Advisors bought 1,000 ImmunityBio shares in Q2 2026, an estimated $7.57K.
  • ImmunityBio made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #1037 holding.
  • Prime Capital Investment Advisors first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.